Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Fangyuan Tian, Zhaoyan Chen, Qiyi Feng
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions
César Fernández‐de‐las‐Peñas, Arkiath Veettil Raveendran, Rocco Giordano, et al.
Microorganisms (2023) Vol. 11, Iss. 12, pp. 2959-2959
Open Access | Times Cited: 25
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Jesus Alfonso Catahay, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 43-58
Closed Access | Times Cited: 23
Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Fangyuan Tian, Qiyi Feng, Zhaoyan Chen
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106870-106870
Open Access | Times Cited: 22
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 22
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis
Gangqiang Sun, Ke Lin, Jingwen Ai, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1505-1513
Closed Access | Times Cited: 5
The effectiveness of dual antiviral treatment against COVID-19
Д.Д. Іванов, А. І. Гоженко, Mariia Ivanova
Journal Of Advanced Pharmacy Education And Research (2025) Vol. 15, Iss. 1, pp. 1-7
Closed Access
Cost-effectiveness of preventive COVID-19 interventions: a systematic review and network meta-analysis of comparative economic evaluation studies based on real-world data
Xiaoyu Tang, Sun Sun, Mevludin Memedi, et al.
Journal of Global Health (2025) Vol. 15
Open Access
Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA
Caixia Gao, Zhihui Liu, Zhen Zou, et al.
Expert Opinion on Drug Safety (2025), pp. 1-8
Closed Access
Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis
Zhaoyan Chen, Fangyuan Tian
Heliyon (2023) Vol. 9, Iss. 9, pp. e20153-e20153
Open Access | Times Cited: 13
Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge
Yu Wang, Danyang Zhao, Wenying Xiao, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 8
Closed Access | Times Cited: 12
Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study
Weijie Wang, Yu‐Hsun Wang, Ching‐Hua Huang, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines
Can Yue, Pengyan Wang, Jinmin Tian, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 13, pp. 4052-4060
Open Access | Times Cited: 11
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 2
“Inflammatory Pathways in Patients with Post-acute Sequelae of COVID-19 – The Role of the Clinical Immunologist”
Matthew Elliott, A. O'Connor, Gailen D. Marshall
Annals of Allergy Asthma & Immunology (2024) Vol. 133, Iss. 5, pp. 507-515
Closed Access | Times Cited: 2
Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis
Zhaoyan Chen, Fangyuan Tian
Annals of Medicine (2023) Vol. 55, Iss. 2
Open Access | Times Cited: 6
Safety Profile of Paxlovid in the Treatment of COVID-19
Bing Lv, Xin Gao, Guoqiang Zeng, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 9, pp. 666-675
Closed Access | Times Cited: 1
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
Behnam Amani, Bahman Amani
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 7, pp. 547-555
Closed Access | Times Cited: 1
Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective
Ee Vien Low, Hoon Shien Teh, Nicholas Yee Liang Hing, et al.
Drugs - Real World Outcomes (2024) Vol. 11, Iss. 2, pp. 299-308
Open Access | Times Cited: 1
Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis
Bahman Amani, Behnam Amani
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0298772-e0298772
Open Access | Times Cited: 1
Real‐world effectiveness of azvudine: Elixir or equivocal answer?
Yuan Gao, Zujin Luo, Zhongjie Hu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 7
Closed Access | Times Cited: 3
Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients
Zhaoyan Chen, Fangyuan Tian, Yachao Zeng
BMC Geriatrics (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 2
High-throughput screening identifies broad-spectrum Coronavirus entry inhibitors
Suman Khan, Efrat Ozer Partuk, Jeanne Chiaravalli, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 110019-110019
Open Access
Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
Zhaoyan Chen, Fangyuan Tian, Ying Zhang
Frontiers in Public Health (2024) Vol. 12
Open Access
The prevalence and factors associated with potentially inappropriate medications in Chinese older outpatients with heart failure
Ying Zhang, Zhaoyan Chen, Fangyuan Tian
BMC Geriatrics (2024) Vol. 24, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top